ACC 2020

Episodes 1-12 of 12

One step closer to controlling LDL-c levels in HoFH with PCSK9i
One step closer to controlling LDL-c levels in HoFH with PCSK9i
ACC 2020
One step closer to controlling LDL-c levels in HoFH with PCSK9i
- Dirk Blom, PhD
Use of ARNI in HFpEF patients reduces NT-proBNP levels
Use of ARNI in HFpEF patients reduces NT-proBNP levels
ACC 2020
Use of ARNI in HFpEF patients reduces NT-proBNP levels
- Jonathan Cunningham, MD
Reduced bleeding with P2Y12i monotherapy after 3 months DAPT after complex PCI
Reduced bleeding with P2Y12i monotherapy after 3 months DAPT after complex PCI
ACC 2020
Reduced bleeding with P2Y12i monotherapy after 3 months DAPT after complex PCI
- Prof. George Dangas, MD, PhD
Stopping with aspirin after 3 months DAPT is safe in a wide range of patients
Stopping with aspirin after 3 months DAPT is safe in a wide range of patients
ACC 2020
Stopping with aspirin after 3 months DAPT is safe in a wide range of patients
- Prof. Freek Verheugt, MD
Mechanistic underpinning of CV benefit observed with icosapent ethyl
Mechanistic underpinning of CV benefit observed with icosapent ethyl
ACC 2020
Mechanistic underpinning of CV benefit observed with icosapent ethyl
- Deepak Bhatt, MD
Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH
Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH
ACC 2020
Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH
- Prof. Frederick Raal
Higher rate of smoking cessation with e-cigarettes compared to counseling
Higher rate of smoking cessation with e-cigarettes compared to counseling
ACC 2020
Higher rate of smoking cessation with e-cigarettes compared to counseling
- Prof. Mark Eisenberg, MD
Added value of sGC stimulator in worsening HFrEF patients
Added value of sGC stimulator in worsening HFrEF patients
ACC 2020
Added value of sGC stimulator in worsening HFrEF patients
- Prof. Paul Armstrong, MD
Oral anticoagulant monotherapy reduces bleeding in AF patients after TAVI
Oral anticoagulant monotherapy reduces bleeding in AF patients after TAVI
ACC 2020
Oral anticoagulant monotherapy reduces bleeding in AF patients after TAVI
- Dr. Jur ten Berg
NOAC non-inferior to heparin in reducing cancer-associated VTE recurrence
NOAC non-inferior to heparin in reducing cancer-associated VTE recurrence
ACC 2020
NOAC non-inferior to heparin in reducing cancer-associated VTE recurrence
- Prof. Menno Huisman
NOAC plus aspirin superior to aspirin alone for preventing major adverse limb and CV events
NOAC plus aspirin superior to aspirin alone for preventing major adverse limb and CV events
ACC 2020
NOAC plus aspirin superior to aspirin alone for preventing major adverse limb and CV events
- Marc Bonaca, MD
Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes
Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes
ACC 2020
Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes
- Deepak Bhatt, MD

Episodes 1-12 of 12

Title

Share on ReachMD